Skip to content

Innovation Labs to Enhance Collaboration

Controlled Evaluation of Innovation Labs for Enhancing Collaboration Among Early Career Scholars in the CTSA Network

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05395286
Enrollment
94
Registered
2022-05-27
Start date
2017-08-03
Completion date
2020-06-25
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Collaboration Attitudes and Behavior

Brief summary

Conduct and evaluate the impact of two week-long Innovation Labs on collaboration attitudes and behavior among early career scholars. Applicants to each Innovation Lab will be screened and then randomized to either the Innovation Lab group or a control group.

Detailed description

Building on the science of team science and preliminary work at the Buffalo and Vanderbilt CTSAs, the investigators worked with industry partner Knowinnovation to implement, assess, and disseminate an innovative and promising method for stimulating and nurturing new transdisciplinary research teams across the CTSA Program consortium: Innovation Labs. The study focused on early career investigators. The study took a translational science approach to identify and test "best practices". To accomplish this, the study critically evaluated the impact of Innovation Labs in two preliminary randomized controlled trials (RCTs). In collaboration with NCATs and broad input from the CTSA network, the investigators developed a clinical and translational research grand challenge focus for each Innovation Lab. A diverse applicant pool of early career investigators invited from every CTSA hub in the consortium was reviewed, and top applicants were randomized to a 5-day residential Innovation Lab or "treatment as usual" control group. Measures of process and outcome were collected from the application phase through 12-month follow-up and aggregated across the two RCTs. Given the preliminary nature of the work and an emerging consensus regarding the science of team science, primary outcomes were measures of the depth and breadth of participants collaborative networks and attitudes towards collaboration, which were predicted to be enhanced in the Innovation Lab group compared to the treatment as usual control group. Initial data on the degree to which Innovation Labs resulted in increased transdisciplinary collaborative output were also examined.

Interventions

BEHAVIORALInnovation Lab

An Innovation Lab is a facilitated 5-day residential event designed to create novel, transdisciplinary and potentially transformative research ideas and proposals to address a specific grand challenge. Participants, along with a director, organizers, subject matter guides, and KI facilitators communally explore the problem space, generate a broad range of ideas, and form transdisciplinary teams to pursue research projects.

Sponsors

State University of New York at Buffalo
Lead SponsorOTHER
National Center for Advancing Translational Sciences (NCATS)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Completion of application and baseline assessment. * Faculty at a NIH CTSA hub institution or regional partner. * Early stage investigators (NIH-defined as "within 10 years of completing his/her terminal research degree or is within 10 years of completing medical residency (or the equivalent)") who are emerging as independent scholars. * Ratings of goodness of fit with the topic of the Innovation Lab. Applications were reviewed for the above criteria and ranked by committee according to goodness of fit with the topic of the Innovation Lab, the quality and quantity of academic productivity and collaboration, and contribution to diversity of perspectives among Lab participants (e.g., biomedical and social/psychological, basic and applied). Top-ranked applicants were retained for randomization to the Innovation Lab group or control group.

Design outcomes

Primary

MeasureTime frameDescription
MATRICx Collaboration Benefits/Motivators Scale15 monthsSelf-report: The Motivation Assessment for Team Readiness, Integration, and Collaboration (MATRICx; Mallinson, Lotrecchiano, et al., 2016) benefits scale includes 17 items that tap into perceived motivators/benefits of collaboration. Each is rated on a 1-4 scale. Scale scores were computed as the mean of all 17 items, for a benefits scale score ranging from 1-4, with higher scores indicating greater collaboration readiness.
MATRICx Collaboration Barriers/Threats Scale15 monthsSelf-report: The Motivation Assessment for Team Readiness, Integration, and Collaboration (MATRICx; Mallinson, Lotrecchiano, et al., 2016) Threats Scale includes 31 barriers to -- or threats of -- collaboration. Each is rated on a 1-4 scale. Scale scores were computed as the mean of all 31 items, for a Barriers/Threats scale score ranging from 1-4, with lower scores indicating greater collaboration readiness.
Transdisciplinary Orientation Scale15 monthsSelf-report: The Transdisciplinary Orientation scale (TDO; Misra, Stokols, \& Cheng, 2015) is a 12-item scale that measures values, attitudes, and beliefs, and conceptual skills and behaviors, that assesses the degree to which participants are oriented towards transdisciplinary collaboration. Items are rated on a five-point scale (1="Strongly Disagree," 5="Strongly Agree"). The total score is the mean of all 12 items, with a resulting 1-5 range, in which higher scores indicate greater transdisciplinary collaboration orientation.
Collaboration Network Size36 Months (18-monts pre- and post-treatment, after excluding articles published within +/-3 months of the Innovation Lab)Objective number of collaborators from published articles on PubMed

Secondary

MeasureTime frameDescription
Self-Reported Number of Grants Submitted Per Year21 months (9 months pre-treatment [obtained at baseline and EOT]; 12 months post-treatment [obtained at 6- and 12-month follow-up])Self-Reported Number of Grants Submitted per Year. For the post-treatment period, the number of grants submitted at 6- and 12-M follow-up were summed. To make the pre-treatment period (which covered only 9 months) comparable to the post-treatment period, the number of grants at baseline and EOT were summed, divided by 9, and then multiplied by 12. Participants who did not report the number of grants submitted were coded as zero for the ITT analysis.
ILab Met Goal - New Collab12 months (End of Treatment [3 months post-baseline], 6-Month Follow-Up [9 months post-baseline], and 12-Month Follow-Up [15 months post-baseline])The Innovation Lab group was asked to rate the degree to which "The Lab met the goal of forming new transdisciplinary collaborations", answering on a 6-point scale (0 = "Strongly Disagree" to 5 = "Strongly Agree"), with higher scores indicating a beneficial effect of the Innovation Lab.
ILab Met Goal - Novel Proposals12 months (End of Treatment [3 months post-baseline], 6-Month Follow-Up [9 months post-baseline], and 12-Month Follow-Up [15 months post-baseline])The Innovation Lab group was asked to rate the degree to which "The Lab met the goal of developing novel grant proposals", answering on a 6-point scale (0 = "Strongly Disagree" to 5 = "Strongly Agree"), with higher scores indicating a beneficial effect of the Innovation Lab.
ILab - Recommend12 months (End of Treatment [3 months post-baseline], 6-Month Follow-Up [9 months post-baseline], and 12-Month Follow-Up [15 months post-baseline])The Innovation Lab group was asked to rate the degree to which "I would recommend an Innovation Lab to a colleague", answering on a 6-point scale (0 = "Strongly Disagree" to 5 = "Strongly Agree"), with higher scores indicating a beneficial effect of the Innovation Lab.
ILab - Positive Impact12 months (End of Treatment [3 months post-baseline], 6-Month Follow-Up [9 months post-baseline], and 12-Month Follow-Up [15 months post-baseline])The Innovation Lab group was asked to rate the degree to which "My experience in the Innovation Lab will have a positive impact on my work at my home institution", answering on a 6-point scale (0 = "Strongly Disagree" to 5 = "Strongly Agree"), with higher scores indicating a beneficial effect of the Innovation Lab.

Countries

United States

Participant flow

Pre-assignment details

Each application was rated by 2-4 raters on a 1-4 scale for bringing diverse expertise to the Innovation Lab topic and fit for the Innovation Lab approach. Applicants with consistently poor scores (\ ≤2) were excluded from RCT participation.

Baseline characteristics

Characteristic
Age, Continuous37.7 Years
STANDARD_DEVIATION 6.2
Ethnicity (NIH/OMB)
Hispanic or Latino
6 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
87 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
11 Participants
Race (NIH/OMB)
Black or African American
1 Participants
Race (NIH/OMB)
More than one race
1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
Race (NIH/OMB)
White
75 Participants
Region of Enrollment
United States
94 participants
Sex: Female, Male
Female
69 Participants
Sex: Female, Male
Male
13 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 470 / 47
other
Total, other adverse events
0 / 470 / 47
serious
Total, serious adverse events
0 / 470 / 47

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 28, 2026